Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.

ABSTRACT: Identifying the presence or absence of a BRAF^V600E mutation is paramount for the management of patients with metastatic colorectal cancer (mCRC) as there are distinct predictive and prognostic implications, as well as unique therapeutic approaches for this molecular subtype. Traditional cytotoxic doublet chemotherapy has historically been ineffective for this poor prognostic group, thereby highlighting the critical need for novel targeted therapies to drive management. Unlike the early success achieved with BRAF-inhibitor monotherapy for patients with BRAF^V600E-mutated metastatic melanoma, response rates were found to only be 5% in early-phase clinical trials for patients with BRAF^V600E mCRC. A deeper understanding of predominant resistance mechanisms in BR

SUBMITTER: Johnson B 

PROVIDER: S-EPMC7583680 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature